Two Of The Cyclos Share At Least Three Ring Carbons (i.e., Bridged) (e.g., Benzomorphans, Etc.) Patents (Class 514/295)
-
Patent number: 7619110Abstract: The present invention provides a prodrug of propofol and crystalline forms thereof, methods of making the propofol prodrug and crystalline forms thereof, pharmaceutical compositions of the propofol prodrug and crystalline forms thereof, methods of using the propofol prodrug and crystalline forms thereof and pharmaceutical compositions thereof to treat diseases or disorders such as headache pain, post-chemotherapy or post-operative surgery nausea and vomiting, neurodegenerative disorders, and mood disorders.Type: GrantFiled: December 22, 2005Date of Patent: November 17, 2009Assignee: XenoPort, Inc.Inventors: Feng Xu, Mark A. Gallop, Vivek Sasikumar, Usha Dilip
-
Patent number: 7612087Abstract: This invention discloses and claims methods for inhibiting bacterial ?-lactamases and treating bacterial infections by inhibiting bacterial ?-lactamases in man or an animal comprising administering a therapeutically effective amount to said man or said animal of a compound, or pharmaceutically acceptable salt thereof, of formula (I) either alone or in combination with a ?-lactamine antibiotic wherein said combination can be administered separately, together or spaced out over time. Pharmaceutical compositions comprising a compound of formula (I), or a combination of a compound of formula (I) and a therapeutically effective amount of a ?-lactamine antibiotic, and a pharmaceutically acceptable carrier are also disclosed and claimed.Type: GrantFiled: July 26, 2004Date of Patent: November 3, 2009Assignee: NovexelInventors: Jozsef Aszodi, Claude Fromentin, Maxime Lampilas, David Alan Rowlands
-
Patent number: 7557119Abstract: 8-Substituted-2,6-methano-3-benzazocines of general structure are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications.Type: GrantFiled: July 21, 2006Date of Patent: July 7, 2009Assignee: Rensselaer Polytechnic InstituteInventor: Mark P. Wentland
-
Publication number: 20090156639Abstract: The present invention relates to composition comprising at least one L-type calcium channel blocker, particularly the compound (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate, in combination with at least one cholinesterase inhibitor, particularly donepezil, and uses thereof in methods of treatment.Type: ApplicationFiled: February 20, 2009Publication date: June 18, 2009Inventors: Crista Trippodi-Murphy, Gregory M. Rose, Axel Unterbeck
-
Publication number: 20090118320Abstract: A compound of Formula I, a pharmaceutically-acceptable salt or a hydrate thereof, wherein R1 is H, or C1-4 alkyl; R2 is H, halogen, or C1, alkyl; R3 is H, halogen, or C1-4 alkyl, and R4 is C1-6 alkyl, aryl; or ?CR3R4 is cyclopentylidene, cyclohexylidene, 1-methylpiperidin-4-ylidene, or inden-1-ylidene; R5 is independently at each occurrence F, Cl, Br, CF3, R9, OR9, NR9R10, NO2, CN, COOR9, O2CR9, CONR9R10, NR9C(O)R10, heterocyclic group, aryl, or a group of Formula II; R6 is H, halogen, or C1-4 alkyl; R7 is H, halogen, or C1-4 alkyl; R8 is H, C1, alkyl group; R9 is H, or C1-6 alkyl; R10 is H, or C1-6 alkyl; R11 is H, or C1-4 alkyl; R12 is H, or C1-4 alkyl; m is 0, 1, or 2; when R5 is F, Cl, Br, CF3, R9, OR9, NR9R10, NO2, CN, COOR9, O2CR9, CONR9R10, NR9C(O)R10, heterocyclic group, or aryl, n is 1, 2, 3, or 4; when R5 is the group of Formula II, n is 0, 1, 2, 3, or 4; x is 0, 1, 2, 3, or 4.Type: ApplicationFiled: November 28, 2008Publication date: May 7, 2009Inventor: Hesheng ZHANG
-
Publication number: 20090060871Abstract: A method for reducing psychological opioid dependence includes selecting a patient addicted to an opioid and administering to the patient an opioid agonist-antagonist for at least 14 days, thereby reducing craving for the opioid in the patient. An opioid agonist-antagonist is administered in a patient needing an average adherence to a treatment protocol of at least 95 percent. A non-injectable formulation containing an agonist-antagonist also is disclosed.Type: ApplicationFiled: October 24, 2008Publication date: March 5, 2009Inventors: Michael Victor VORONKOV, Efim David NEZHINSKY, Levon Gevorkovich ISAKULYAN, Daria Alexandrovna OCHERET
-
Publication number: 20090047234Abstract: The present invention concerns a method of administering at least one active pharmaceutical agent to a patient in need thereof, which method comprises the intranasal administration of a composition comprising a therapeutically effective amount of this agent, phospholipids, one or more C2-C4 alcohols and water, wherein the concentrations of the phospholipids and the one or more alcohols in the composition are in the ranges of 0.2 to 10% and 12 to 30% by weight, respectively, with the water content of said composition being not less than 30% by weight, the phospholipids forming vesicles in said composition. Further are disclosed pharmaceutical compositions and combinations suitable for intranasal delivery.Type: ApplicationFiled: March 28, 2008Publication date: February 19, 2009Inventors: Elka Touitou, Biana Godin, Shaher Duchi
-
Publication number: 20090048234Abstract: The present invention provides compositions and methods for preventing, treating or reversing neuronal dysfunction in a mammal resulting from exposure to organophosphate nerve agents, organophosphate insecticides and incapacitating agents of the central nervous system (CNS); CNS injury, including traumatic brain injury, neurologic complications of cardiac surgery, perinatal asphyxia, and stroke, spinal cord injury, and peripheral nerve injury; and neuronal disorders associated with the loss of motor function including post-polio syndrome, amyotrophic lateral sclerosis, myasthenia gravis, Parkinson's disease and Rett syndrome; neurodegenerative disorders including Alzheimer's disease, mild cognitive impairment and schizophrenia; and cognitive impairment associated with aging.Type: ApplicationFiled: September 17, 2004Publication date: February 19, 2009Inventor: Franklin Volvovitz
-
Publication number: 20090030032Abstract: The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is represented by the formula: wherein, R1 is a 5- to 6-membered ring group which may be substituted; X1 is a bond or the like; ring A is a 5- to 6-membered ring group which may be substituted; ring B is a 8- to 10-membered ring group which may be substituted; X2 is a bivalent group of 1 to 4 atoms; Z1 is a bivalent cyclic ring group or the like; Z2 is a bond or the like; and R2 is an amino group, a nitrogen-containing heterocyclic group which may be substituted or the like, or a salt thereof.Type: ApplicationFiled: May 12, 2008Publication date: January 29, 2009Inventors: Mitsuru Shiraishi, Masanori Baba, Katsuji Aikawa, Naoyuki Kanzaki, Masaki Seto, Yuji Iizawa
-
Publication number: 20090022790Abstract: The present invention relates to co-extruded pharmaceutical compositions and dosage forms including an active agent, such as an opioid agonist, and an adverse agent, such as an opioid antagonist. Such compositions and dosage forms are useful for preventing or discouraging tampering, abuse, misuse or diversion of a dosage form containing an active pharmaceutical agent, such as an opioid. The present invention also relates to methods of treating a patient with such a dosage form, as well as kits containing such a dosage form with instructions for using the dosage form to treat a patient.Type: ApplicationFiled: September 23, 2008Publication date: January 22, 2009Inventors: Robert P. Flath, John K. Masselink
-
Publication number: 20090017015Abstract: The invention relates to the use of a Dipeptidyl peptidase IV inhibitor (DPP-IV inhibitor) or a pharmaceutically acceptable salt thereof for the prevention, delay of progression or the treatment of neurodegenerative disorders, cognitive disorders and for improving memory (both short term and long term) and learning ability.Type: ApplicationFiled: February 18, 2005Publication date: January 15, 2009Inventor: Thomas Edward Hughes
-
Publication number: 20090005352Abstract: The present invention provides propofol prodrugs, methods of making propofol prodrugs, pharmaceutical compositions of propofol prodrugs and methods of using propofol prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting.Type: ApplicationFiled: June 26, 2007Publication date: January 1, 2009Applicant: XenoPort, Inc.Inventors: Feng Xu, Mark A. Gallop
-
Publication number: 20080312189Abstract: The invention provides methods for treating and/or preventing cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) in a patient in need thereof by administering a therapeutically effective amount of at least one cholinesterase inhibitor. The invention also provides methods for treating and/or preventing neurovascular diseases caused by one or more mutations of the human Notch3 gene by administering a therapeutically effective amount of at least one cholinesterase inhibitor. In one embodiment, the cholinesterase inhibitor is donepezil, a stereoisomer thereof and/or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 4, 2005Publication date: December 18, 2008Applicant: EISAI CO., LTD.Inventor: Raymond Pratt
-
Publication number: 20080312268Abstract: Substituted tricyclic piperidone derivatives corresponding to Formula I: a method for producing such compounds; pharmaceutical compositions containing such compounds, and the use of such compounds to treat pain, depression, urinary incontinence, diarrhea, pruritus, alcohol and drug abuse, drug dependency, lethargy and/or anxiety.Type: ApplicationFiled: June 20, 2008Publication date: December 18, 2008Applicant: Gruenenthal GMBHInventors: Stefan Schunk, Stefan Oberboersch, Hagen-Heinrich Hennies, Martin Maier, Anton Khartulyari
-
Publication number: 20080306019Abstract: Provided herein is a method of protecting a neuron from dysfunction induced by an HIV neurotoxin, comprising contacting the cell with a therapeutically effective dose of a dopamine D1 receptor agonist. Also provided is a method of treating or preventing HIV-1 associated dementia (HAD) in a subject in need of such treatment or prevention, comprising administering to the subject a therapeutically effective dose of a dopamine D1 receptor agonist and estrogenic compound.Type: ApplicationFiled: May 3, 2006Publication date: December 11, 2008Inventors: Rosemarie M. Booze, Charles Mactutus
-
Publication number: 20080234311Abstract: The present invention provides a method for the detection and quantification of A?1-40 produced in native cell types and tissues. Also provided are assays and kits to determine the effect of compounds on the production of amyloid ? peptides.Type: ApplicationFiled: November 19, 2007Publication date: September 25, 2008Inventors: Jinhe Li, Murali Gopalakrishnan
-
Publication number: 20080226759Abstract: A system for treating addictions includes genetic testing to determine the presence of allelic variants of genes shown to be associated with impulsive/addictive behaviors and a tailored rehabilitation regimen of specific physical exercise, special diet and particular dietary supplements to optimize the way mood elevation is achieved in the patient. The system further includes individual and group counseling and initial oxygen therapy. The genetic testing assesses the presence of gene polymorphism in at least one of D2 dopamine receptor gene (DRD2), dopamine transporter gene (DAT1), dopamine beta-hydroxylase gene (DBH) and serotonin transporter (SERT) gene. The dietary supplements are tailored to stimulate production of neuromediators or neurotransmitters, depending upon the polymorphism determined. The exercises include static and dynamic routines also tailored to the results of the genetic testing.Type: ApplicationFiled: March 15, 2007Publication date: September 18, 2008Inventor: Yakov Marshak
-
Publication number: 20080193561Abstract: The present invention relates to a preparation suitable for the prevention and/or treatment of vascular disorders, comprising the following fractions: fraction a) consisting of long chain polyunsaturated fatty acids; fraction b) consisting of phospholipids, which fraction contains at least two different phospholipids selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine. fraction c) consisting of compounds which are a factor in methionine metabolism, which fraction contains at least one member selected from the group consisting of folic acid, vitamin B12, vitamin B6, magnesium and zinc.Type: ApplicationFiled: April 14, 2008Publication date: August 14, 2008Inventors: Amanda Johanne Kiliaan, Robert Johan Joseph Hageman
-
Publication number: 20080176793Abstract: This invention provides novel methods of treatment to ameliorate or prevent cognitive disorder/dysfunction in pre- or asymptomatic subject having one or more mutations in the Huntington gene. The methods involve increasing the expression or activity of the neurotrophin BDNS in the brain of said subject.Type: ApplicationFiled: September 18, 2007Publication date: July 24, 2008Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Danielle Simons, Gary Lynch, Eniko Kramar
-
Publication number: 20080090859Abstract: The instant invention relates to the use of compounds that are effective as selective opiate receptor modulators for the manufacture of a pharmaceutical for the diagnosis, prophylaxis and/or the treatment of neuropathy, the clinical pictures and symptoms associated therewith, and related disorders, and to pharmaceutical compositions, comprising one or more of said modulator compounds.Type: ApplicationFiled: October 14, 2004Publication date: April 17, 2008Applicant: TIOGA PHARMACEUTICALS, INC.Inventor: Gerd Bartoszyk
-
Patent number: 7348431Abstract: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a benzazocine moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.Type: GrantFiled: April 8, 2003Date of Patent: March 25, 2008Assignee: Merck & Co., Inc.Inventor: Annette Kim
-
Publication number: 20080039463Abstract: Compositions of flupirtine for management of neuropathic or inflammatory pain optionally including one or more other analgesics including opiates, NSAIDS and other active agents in immediate and controlled release forms. Methods and systems for administration of these compositions.Type: ApplicationFiled: December 16, 2004Publication date: February 14, 2008Applicant: CNSBio Pty LtdInventors: Raymond Nadeson, Adam Paul Tucker, Colin Goodchild
-
Patent number: 7253283Abstract: Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein B, J, K, Z, R, Ra, Rb, Rc, Rd, Rq, Rw, m and n are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.Type: GrantFiled: January 13, 2005Date of Patent: August 7, 2007Assignee: Bristol-Myers Squibb CompanyInventors: David S. Weinstein, John L. Gilmore, James Sheppeck, Bingwei Vera Yang, Soong-Hoon Kim, Wayne Vaccaro
-
Patent number: 7205300Abstract: This invention is directed to compounds of the formula (I): and their pharmaceutically acceptable salts, wherein R1, R2, and R3 are as defined herein; intermediates for the synthesis of such compounds, pharmaceutical compositions containing such compounds; and methods of using such compounds in the treatment of neurological and psychological disorders.Type: GrantFiled: January 3, 2003Date of Patent: April 17, 2007Assignee: Pfizer IncInventors: Jotham Wadsworth Coe, Paige Roanne Palmer Brooks
-
Patent number: 7144882Abstract: This invention is directed to compounds of the formula (I): and their pharmaceutically acceptable salts, wherein R1, R2, and R3 are as defined herein; intermediates for the synthesis of such compounds, pharmaceutical compositions containing such compounds; and methods of using such compounds in the treatment of neurological and psychological disorders.Type: GrantFiled: January 3, 2003Date of Patent: December 5, 2006Assignee: Pfizer IncInventors: Jotham Wadsworth Coe, Paige Roanne Palmer Brooks
-
Patent number: 7041674Abstract: A compound of formula 1 wherein X?, A, R1, R2, R3, and R4 may have the meanings given in the claims and in the specification, processes for preparing them, their use in pharmaceutical compositions, and methods of treating patients using them.Type: GrantFiled: November 20, 2003Date of Patent: May 9, 2006Assignee: Boehringer Ingelhiem Pharma GmbH & Co. KGInventors: Steffen Breitfelder, Matthias Hoffmann, Matthias Grauert, Michael P. Pieper, Georg Speck
-
Patent number: 6982271Abstract: The present invention provides compounds, specifically novel tropane analogs, capable of acting as inhibitors of reuptake of monoamines. In preferred embodiments, these compositions are selective inhibitors of serotonin and/or norepinephrine reuptake. Also provided herein are pharmaceutical compositions comprising novel tropane analogs and a pharmaceutically acceptable carrier, and methods for treating conditions in which inhibition of reuptake of monoamines is desired. The inventive compositions as described herein are also useful for medical therapy and diagnosis.Type: GrantFiled: September 27, 2000Date of Patent: January 3, 2006Assignee: Georgetown UniversityInventors: Alan P. Kozikowski, Wolfgang Alexander Hoepping
-
Patent number: 6964969Abstract: A nutritional supplement composition for normalizing impaired or deteriorating neurological function in humans is composed of: at least one agent which promotes synthesis of ATP and/or creatine phosphate in the body, at least one antioxidant for scavenging free radicals in at least one pathway in the body; at least one agent for normalizing or maintaining membrane function and structure in the body; at least one agent for normalizing or maintaining normal neurotransmitter function in the body; at least one agent for down-regulating cortisol action; and at least one agent for suppressing activation of apoptotic pathways in the body.Type: GrantFiled: April 19, 2001Date of Patent: November 15, 2005Inventor: Edward Larry McCleary
-
Patent number: 6939867Abstract: Sulfamide compounds having formula (I) are described as well as their use in the treatment of diseases dependent on the signaling pathways associated with ?-adrenergic receptors, such as obesity, diabetes, hypertension, gastrointestinal hypo- or hyper-motility and cardiovascular diseasesType: GrantFiled: February 28, 2002Date of Patent: September 6, 2005Assignee: Pfizer Inc.Inventors: Robert L. Dow, Ernest S. Paight
-
Patent number: 6887884Abstract: Compounds of the formula and their pharmaceutically acceptable salts, wherein R1, R2, and R3 are defined as in the specification, intermediates in the synthesis of such compounds, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of neurological and psychological disorders.Type: GrantFiled: February 13, 2002Date of Patent: May 3, 2005Assignee: Pfizer IncInventors: Jotham Wadsworth Coe, Paige Roanne Palmer Brooks
-
Patent number: 6878700Abstract: The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immunune diseases, to pharmaceutical compositions containing these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.Type: GrantFiled: March 31, 2000Date of Patent: April 12, 2005Assignee: Abbott LaboratoriesInventors: James Link, Gang Liu, ZhongHua Pei, Tom von Geldern, Martin Winn, Zhili Xin, Steven A. Boyd, Gui-Dong Zhu, Jennifer C. Freeman, Indrani W. Gunawardana, Michael A. Staeger, Hwan-Soo Jae, John K. Lynch, Sheldon Wang
-
Patent number: 6867203Abstract: The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immune diseases and cerebral vasospasm, to pharmaceutical compositions containing these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.Type: GrantFiled: December 1, 2003Date of Patent: March 15, 2005Assignee: Abbott LaboratoriesInventor: Indrani W. Gunawardana
-
Publication number: 20040266813Abstract: Sustained-release microspheres of Huperzine A compounds, the preparation and use thereof, said sustained-release microspheres comprise Huperzine A compounds represented by the formula (Ia) and biodegradably pharmaceutically acceptable polymer excipients, 1Type: ApplicationFiled: August 23, 2004Publication date: December 30, 2004Inventors: Wanhui Liu, Jilun Song, Dafeng Chu, Ke Liu
-
Publication number: 20040259901Abstract: This invention features opioid compounds having activity at kappa and mu receptors, methods for preparing the mu/kappa opioids, and methods for the treatment of pain or a dopamine dysregulation disease, such as schizophrenia, attention deficit hyperactivity disorder (ADHD), attention deficit hyperactivity disorder (ADD), Parkinson's disease, hyperprolactinemia, depression, and addiction.Type: ApplicationFiled: November 18, 2003Publication date: December 23, 2004Inventors: John L. Neumeyer, Ao Zhang
-
Patent number: 6828311Abstract: The invention relates to a new formulation containing Bill 890 or one of the pharmaceutically acceptable salts thereof for parenteral administration.Type: GrantFiled: May 28, 2003Date of Patent: December 7, 2004Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Bernd Kruss, Annerose Mauz, Karin Ruehr, Jean Marie Stassen, Claus Veit, Klaus Wagner
-
Publication number: 20040242625Abstract: Intranasal delivery methods and compositions for the delivery of dopamine receptor agonists are provided which are effective for the amelioration of erectile dysfunction in a mammal without causing substantial intolerable adverse side effects to the mammal. Nasally administered compositions for treating male erectile dysfunction in a mammal are also provided which include a therapeutically effective amount of a dopamine receptor agonist which has been dispersed in a system to improve its solubility and/or stability.Type: ApplicationFiled: April 21, 2004Publication date: December 2, 2004Applicant: Nastech Pharmaceutical Company, Inc.Inventors: Raja G. Achari, Shamim Ahmed, Charanjit R. Behl, Jorge C. deMeireles, Tianquing Liu, Vincent D. Romeo, Anthony P. Sileno
-
Publication number: 20040242624Abstract: Intranasal delivery methods and compositions for the delivery of dopamine receptor agonists are provided which are effective for the amelioration of erectile dysfunction in a mammal without causing substantial intolerable adverse side effects to the mammal. Nasally administered compositions for treating male erectile dysfunction in a mammal are also provided which include a therapeutically effective amount of a dopamine receptor agonist which has been dispersed in a system to improve its solubility and/or stability.Type: ApplicationFiled: April 21, 2004Publication date: December 2, 2004Applicant: Nastech Pharmaceutical Company, Inc.Inventors: Raja G. Achari, Shamim Ahmed, Charanjit R. Behl, Jorge C. deMeireles, Tianquing Liu, Vincent D. Romeo, Anthony P. Sileno
-
Publication number: 20040242626Abstract: Intranasal delivery methods and compositions for the delivery of dopamine receptor agonists are provided which are effective for the amelioration of erectile dysfunction in a mammal without causing substantial intolerable adverse side effects to the mammal. Nasally administered compositions for treating male erectile dysfunction in a mammal are also provided which include a therapeutically effective amount of a dopamine receptor agonist which has been dispersed in a system to improve its solubility and/or stability.Type: ApplicationFiled: April 21, 2004Publication date: December 2, 2004Applicant: Nastech Pharmaceutical Company, Inc.Inventors: Raja G. Achari, Shamim Ahmed, Charanjit R. Behl, Jorge C. deMeireles, Tianquing Liu, Vincent D. Romeo, Anthony P. Sileno
-
Publication number: 20040220205Abstract: An efficient pharmaceutical formulation for the treatment of an affliction selected from the group consisting of Parkin-son's disease, restless legs syndrome, male erectile dysfunc-tion and female sexual dysfunction is disclosed. Said composition comprises at least one member selected from the group consisting of apomorphine, 6aR-(-)-N-propyl-norapomorphine and their derivatives and pro-drugs thereof in the form of the base or the pharmaceutically acceptable salts or solvates thereof as an active ingredient in a pharmaceutical prepara-tion suited for oral/intraduodenal administration.Type: ApplicationFiled: April 30, 2004Publication date: November 4, 2004Inventors: Hakan Wikstrom, Durk Dijkstra, Thomas Ivo Franciscus Hubert Cremers
-
Publication number: 20040204441Abstract: Intranasal delivery methods and compositions for the delivery of dopamine receptor agonists are provided which are effective for the amelioration of erectile dysfunction in a mammal without causing substantial intolerable adverse side effects to the mammal. Nasally administered compositions for treating male erectile dysfunction in a mammal are also provided which include a therapeutically effective amount of a dopamine receptor agonist which has been dispersed in a system to improve its solubility and/or stability.Type: ApplicationFiled: April 21, 2004Publication date: October 14, 2004Applicant: Nastech Pharmaceutical Company, Inc.Inventors: Raja G. Achari, Shamim Ahmed, Charanjit R. Behl, Jorge C. deMeireles, Tianquing Liu, Vincent D. Romeo, Anthony P. Sileno
-
Publication number: 20040204440Abstract: A composition, device, and method for treating sexual dysfunction via inhalation is provided which comprises inhaling a dose of apomorphine or pharmaceutically acceptable salt(s) or ester(s) thereofType: ApplicationFiled: July 17, 2003Publication date: October 14, 2004Inventors: John Nicholas Staniforth, David Alexander Vodden Morton, Michael Tobyn, Stephen Eason, Quentin Harmer, David Ganderton
-
Publication number: 20040204439Abstract: A composition, device, and method for treating sexual dysfunction via inhalation is provided which comprises inhaling a dose of a powder composition, the powder composition comprising apomorphine or pharmaceutically acceptable salts thereof. Preferably, the powder composition further includes a carrier material, the carrier material has an average particle size of from about 40 to about 70 microns, and at least 90 percent of said apomorphine has a particle size of 5 microns or less.Type: ApplicationFiled: April 14, 2003Publication date: October 14, 2004Inventors: John Nicholas Staniforth, David Alexander Vodden Morton, Michael Tobyn, Stephen Eason, Quentin Harmer, David Ganderton
-
Publication number: 20040176321Abstract: The present invention relates to a pharmaceutical composition in aqueous solution form useful for parenteral application to a subject for treatment or prevention of infective disease. In particular the present invention relates to such a composition having as an active agent S-(−)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, S-(−)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid 0.2 hydrate or S-(−)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid arginine salt or a benzoquinolizine-2-carboxylic acid antibiotic drug. The field of the invention also includes processes for the preparation of such a composition, the use of such a composition in preparation of a medicament, and to the therapeutic or prophylactic use of such a composition.Type: ApplicationFiled: December 31, 2003Publication date: September 9, 2004Applicant: WOCKHARDT LIMITEDInventors: Dilip G. Saoji, Rajendra N. Nagori, Ravindra D. Yeole, Nitin Shetty, Milind C. Shukla, Noel J. de Souza
-
Patent number: 6784186Abstract: This invention relates to novel structural analogues and derivatives of compounds with general analgesic or related pharmacological activity. In particular the invention relates to derivatives of opioid compounds, particularly morphine and related compounds, in which an opioid compound is linked via the nitrogen at position 17 to a spacer group, which in turn is linked to a charged group, or a pharmaceutically acceptable salt thereof. In particularly preferred embodiments the opioid compound is morphine, codeine, or buprenorphine.Type: GrantFiled: November 20, 2000Date of Patent: August 31, 2004Inventors: Roy W. Jackson, Kamani R. Subasinghe, Alan L. A. Boura
-
Patent number: 6750224Abstract: The present invention relates to optically pure S-(−)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof, substantially free of their R-(+)-isomers, to processes for preparation of the optically pure S-(−)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof substantially free of their R-(+)-isomers, and to pharmaceutical compositions comprising the S(−)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof.Type: GrantFiled: August 17, 2000Date of Patent: June 15, 2004Assignee: Wockhardt LimitedInventors: Mahesh Vithalbhai Patel, Shivkumar Agarwal, Sreenivas Kandepu, Nitin Shetty, Dilip Upadhyay, Nishith Chaturvedi, Abraham Thomas, Noel John De Souza, Habil Fakhruddin Khorakiwala
-
Publication number: 20040101484Abstract: Intranasal delivery compositions and methods for the delivery of dopamine receptor agonists are provided which are effective for the treatment14 of sexual dysfunction in a mammal without causing substantial intolerable adverse side effects to the mammal, in particular adverse nasal effects. Nasally administered compositions for treating sexual dysfunction in a mammal are also provided which include a therapeutically effective amount of a dopamine receptor agonist which has been dispersed in a system to improve its solubility and/or stability.Type: ApplicationFiled: November 5, 2003Publication date: May 27, 2004Inventors: Charanjit R. Behl, Vincent D. Romeo, Raja G. Achari, Shamin Ahmed, Jorge C. Demeireles, Tianquing Liu, Anthony P. Sileno
-
Publication number: 20040087513Abstract: The invention relates to new drug combinations based on sodium channel blockers 1 and magnesium salts 2, processes for the preparation thereof as well as the use thereof for preparing pharmaceutical compositions for the treatment of ischaemic conditions.Type: ApplicationFiled: July 2, 2003Publication date: May 6, 2004Applicant: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Judith Duettmann, Thomas Weiser
-
Publication number: 20040077679Abstract: The present invention is directed to a method for treating the metabolic syndrome or Type 2 diabetes, comprising the step of administering to a subject in need of such treatment a pharmaceutical composition comprising (1) at least one compound that stimulates an increase in central dopaminergic neuronal activity level in the subject, and (2) at least one compound that stimulates a decrease in central noradrenergic neuronal activity level in the subject. The present invention is also directed to a method for treating the metabolic syndrome or Type 2 diabetes, comprising the step of administering to a subject in need of such treatment at least one compound that simultaneously stimulates (1) an increase in central dopaminergic neuronal activity level, and (2) a decrease in central noradrenergic neuronal activity level. The present invention is also directed to pharmaceutical compositions that include the above compounds and a pharmaceutically acceptable carrier.Type: ApplicationFiled: July 25, 2003Publication date: April 22, 2004Inventor: Anthony H. Cincotta
-
Publication number: 20040072860Abstract: Novel piperazin-2-one containing compounds of general formulae (I) or (II), including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivative having activity against mammalian factor Xa arc described. Compositions containing such compounds are also described. The compounds and the compositions are useful in vitro or in vivo for preventing or treating conditions in mammals characterized by undesired thrombosis.Type: ApplicationFiled: August 8, 2003Publication date: April 15, 2004Inventors: Bing-Yan Zhu, Ting Su, Wenhao Li, Erik A. Goldman, Penglie Zhang, Zhaozhong Jon Jia, Robert M. Sacrborough
-
Publication number: 20040063736Abstract: The subject of the present invention is a new combination of active ingredients consisting of alfuzosine and apomorphine, and pharmaceutical compositions containing them, for ameliorating and/or treating erectile dysfunction in male patients.Type: ApplicationFiled: July 17, 2003Publication date: April 1, 2004Inventors: Sonia Arbilla, Juan Fernando Ramirez